I’ve discussed what a shareholder derivative case is (an action on behalf of the corporation against its officers and directors).
A new wave of derivative litigation is happening for pharmaceutical companies that are investigated and fined by the U.S. for violations of the Foreign Corrupt Practices Act, i.e., bribing foreign officials.
J&J is the latest suit in what is sure to be a long line of cases to come that will assert that boards of directors should implement controls to discourage bribing government officials.
{ 0 comments… add one now }